Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers

By sjmartinez • October 4, 2023

O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers. Mol Cancer Ther. 2023 Oct 3. doi: 10.1158/1535-7163.MCT-23-0353. Epub ahead of print. PMID: 37788341.

Tags: Hematology/Oncology, Publications

Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes

Smick AH, Brennan L, Silverstein J, Salani R, Konecny G, Chase DM. Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure[...]

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller[...]

Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab

Kye Y, Marshalek J, Wise D, Peng S, Hwang A. Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab. Clin[...]